湯臣倍健(300146.SZ)跌停 成交額放大至近11億元
格隆匯6月29日丨24日晚發佈定增公告的湯臣倍健(300146.SZ)今日盤中跌停報19.81元,目前跌停封單超1.4萬手,換手率6%,成交額已放大至10.78億元,最新總市值313億元。有分析人士稱,美國最大保健品GNC破產或是湯臣倍健跌停導火線。另外,24日晚公司披露擬非公開發行募集資金不超過36.1億元人民幣,料攤薄每股收益。根據公司公告,本次發行數量不超過1.6億股,募集資金將用於生產基地項目、補充流動資金等。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.